Grand Opening in Germany!
YH001 & YH003 Phase II Clinical Trials
Tens of Millions in Financing
RenMice HiTS Platform Financing
Biocytogen & Eucure
Biocytogen merges with Eucure Biopharma, aiming to create innovative antibody drugs to improve human health worldwide.
YH001 & YH002 Approved
Anti-CTLA-4 and OX40 antibodies YH001 and YH002 approved for clinical trials in China
RenMice HiTS Platform Launch
RenMice HiTS Platform initiative launched, signifying Biocytogen's transformation to a biotechnology company
YH002 Clinical Trials Approved in U.S.
Anti-OX40 antibody YH002 was approved for clinical trials in the United States
YH001 Clinical Trials Approved in U.S.
Anti-CTLA-4 antibody YH001 was approved for clinical trials in the United States
Rise of RenMab
Developed RenMab Mouse, a fully human antibody mouse model; Closed D-round funding in July
Received C-round funding from SDIC Venture Capital, 3E Bioventures, Cowin Capital Group and Oriza Holdings
Boston & Shanghai Sites
Boston and Shanghai sites opened for business
Haimen Animal Center Opens
Haimen Animal Center began operations; AAALAC accreditation earned; Antibody Discovery Service Platform established; B-NDG™ and a comprehensive variety of humanized immune checkpoint mice were supplied to clients
Preclinical Services & New Funding
Established preclinical services platform; Raised B-round funding from SDIC Venture Capital and BioVeda China Fund
New Mouse Models Developed
Developed B-NDG™ mice (highly immune deficient) and B-hPD-1, the first humanized immune-checkpoint mouse model
ESC/HR Gene Editing Platform
Developed ESC/HR-based gene editing technology platform and delivered gene editing services to our first customer.